Summary
Becton Dickinson & Co. (BDX) reported strong financial results for the third quarter and the first nine months of fiscal year 2008, showcasing significant year-over-year growth in revenues and operating income across its key segments: Medical, Diagnostics, and Biosciences. Total revenues increased by 14.5% to $1.868 billion for the quarter and by 13.0% to $5.320 billion for the nine-month period. This growth was driven by volume increases, favorable foreign currency translation, and strategic pricing, with notable strength in international markets. The company also saw an improvement in its balance sheet, with cash and equivalents increasing substantially and its debt-to-capital ratio remaining healthy. Profitability metrics showed robust improvement, with operating income growing by 25% for the quarter and 36.9% for the nine-month period. Diluted earnings per share from continuing operations also saw substantial growth, reflecting the company's operational efficiency and revenue expansion. Despite some pressures from increased raw material costs and manufacturing start-up expenses impacting gross profit margins, BDX demonstrated effective cost management, with selling and administrative expenses as a percentage of revenue decreasing. The company continues to invest in research and development to fuel future growth, with R&D expenses increasing by 7.6% for the quarter.
Financial Highlights
30 data points| Revenue | $1.85B |
| Cost of Revenue | $905.39M |
| Gross Profit | $943.95M |
| SG&A Expenses | $435.81M |
| Operating Expenses | $1.44B |
| Operating Income | $408.22M |
| Interest Expense | $9.02M |
| Net Income | $297.09M |
| EPS (Basic) | $1.22 |
| EPS (Diluted) | $1.18 |
Key Highlights
- 1Total revenues for the third quarter of fiscal year 2008 increased by 14.5% to $1.868 billion, compared to $1.631 billion in the prior year quarter. For the nine months ended June 30, 2008, revenues grew 13.0% to $5.320 billion.
- 2Operating income saw substantial growth, increasing by 25.0% to $409.6 million for the third quarter and by 34.2% to $1.154 billion for the nine-month period.
- 3Diluted earnings per share from continuing operations rose to $1.18 for the third quarter, a 24.2% increase from $0.95 in the prior year, and to $3.34 for the nine-month period, up from $2.38 in the prior year.
- 4International revenues showed strong performance, increasing by 24% in the third quarter, driven by a 13% favorable impact from foreign currency translation.
- 5The company acquired Cytopeia Inc. on May 12, 2008, for $43.0 million to strengthen its position in cell-based research, with the acquisition not materially impacting the consolidated results.
- 6Cash and equivalents increased significantly to $735.9 million at June 30, 2008, from $511.5 million at September 30, 2007, reflecting strong operating cash flow.
- 7Despite pressures from increased raw material costs and manufacturing start-up costs, the company managed its expenses, with selling and administrative expenses as a percentage of revenue decreasing in both the quarter and nine-month periods.